XORTX Therapeutics

Company snapshot

XORTX Therapeutics is a pharma organization headquartered in VANCOUVER, A1, USA. It trades on NYSE under ticker XRTX. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for XORTX Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for XORTX Therapeutics.

1. Aug 9, 2022 Patent grant

   Xanthine oxidase inhibitor formulations

View all clinical trial activity →

• What is XORTX Therapeutics?

  XORTX Therapeutics is a pharma organization headquartered in VANCOUVER, A1, USA. It trades on NYSE under ticker XRTX. NovaPharmaNews links 0 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• Is XORTX Therapeutics publicly traded?

  Yes. XORTX Therapeutics is listed with ticker XRTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does XORTX Therapeutics develop or market?

  No drug profiles are currently linked to XORTX Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for XORTX Therapeutics?

  Browse related news and pipeline sections on this page for coverage and ClinicalTrials.gov-linked program updates.

• What therapeutic areas does XORTX Therapeutics focus on?

  No specific therapeutic focus areas are currently identified for XORTX Therapeutics in our database.